Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Endometrial Neoplasms 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 25Paclitaxel 20Carboplatin 17Bevacizumab 12Specimen Handling 10Letrozole 10abemaciclib 7dostarlimab 6Taxes 6Blood Specimen Collection 6Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Fulvestrant 5Drug Therapy 5Doxorubicin 5Cisplatin 5Biopsy 5olaparib 4lenvatinib 4atezolizumab 4Radiotherapy 4Progestins 4Observation 4Nivolumab 4Megestrol Acetate 4Immunoglobulin G 4Gemcitabine 4trastuzumab deruxtecan 3palbociclib 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Endometrial Neoplasms × AZD5305 × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡